# Indaptus Therapeutics, Inc. (INDP)

> Source: Nexqual · https://nexqual.com/INDP · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Indaptus Therapeutics, Inc. (INDP), nexqual.com/INDP" · informational, not investment advice.

**Price:** USD 3.16 (+5.69% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 2.99 · day 2.87–3.22 · 52w 0.92–5.96 · market cap $421M · NCM

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -12.9% vs S&P 500 +13.4%; 5Y -98.4% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$7.7M | -$14.9M | -$16.4M | -$15.4M | -$19.8M | -$14.8M |
| Net income | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M | -$15.4M |
| EPS (diluted) | -$52.92 | -$48.44 | -$51.24 | -$44.96 | -$21.58 | — |
| Free cash flow | -$11.3M | — | — | — | — | — |
| Cash + short-term investments | $39.1M | $26.4M | — | — | $8.5M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 37.0x · Earnings yield -3.66%

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -12.9% | -98.4% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -13.0% | -56.4% |
| Volatility (annualized) | 182.7% | 113.9% |
| Max drawdown | -80.3% (Jun 2026→Aug 2026) | -99.5% (Nov 2021→Aug 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/INDP · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in INDP's own 10-K filed 2026-03-17 (https://www.sec.gov/Archives/edgar/data/1857044/000149315226010585/form10-k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Merck (MRK) | "at Merck Research Laboratories, including external research, out-licensing regional deals, and academic alliances." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-03-31) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2026-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |